China Infectious Disease Treatment Market Share, Size, Emerging Trends and Growth, Analysis, Overview and Forecasts 2016-2020

Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.

Technavio's analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.

Browse Detail Report With TOC @

Covered in this report

The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

Technavio's report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
-F. Hoffmann-La Roche
-Gilead Sciences
-Johnson & Johnson

Other prominent vendors
-Adenovir Pharma
-Celsus therapeutics
-Eleven Biotherapeutics
-Ferrer International
-Griffin Discoveries
-InSite Vision
-Insmed Incorporated
-KaloBios Pharmaceuticals
-Lytix Biopharma...